These findings suggest that HCC cells are sensitive to CTLA-4/PD-1/PD-L1 blockade, which is consistent with prior observations with combinations such as nivolumab plus ipilimumab (12) and tremelimumab plus durvalumab (11). Here, CTLA4 is linked to hepatocellular carcinoma.